

KURZPROTOKOLL
GM-IMAB-001-03

Öffentlicher Titel	Phase II Studie zu IMAB362 in Kombination mit Epirubicin/Oxaliplatin/Capecitabin (EOX) bei CLDN18.2 positivem Magen-/Ösophagusadenokarzinom
Wissenschaftl. Titel	A Randomized Phase II Multicenter, Open-Label Study Evaluating the Efficacy and Safety of IMAB362 in Combination With the EOX Regimen (Plus ZA/IL-2) as First-Line Treatment of Patients With CLDN18.2-positive Adenocarcinomas of the Stomach, the Esophagus or the Gastroesophageal Junction.
Kurztitel	GM-IMAB-001-03
Studienart	multizentrisch, prospektiv, Therapiestudie, randomisiert, offen/unverblindet, Pharma-Studie, zweiarmig
Studienphase	Phase II
Erkrankung	Verdauung: Magen-/Speiseröhrenkrebs (Magen-/Ösophaguskarzinom): Erstlinie
Ziele	<ul style="list-style-type: none">- PFS- Safety and tolerability of IMAB362 in combination with EOX- survival rate at 12 month- Overall survival (OS)- time to progression (TTP)- Objective tumor response rate (ORR)- disease control rate (DCR)- duration of response (DOR)
Einschlusskriterien	<ul style="list-style-type: none">- Histologically confirmed adenocarcinoma of the stomach, the esophagus or the gastroesophageal junction- Inoperable locally advanced disease or resections with R2 outcome or recurrent or metastatic disease- CLDN18.2 expression confirmed by immunohistochemistry in paraffin embedded tumor tissue sample- Measurable and/or non-measurable disease as defined according to RECISTv1.1- Age \geq 18 years- Written Informed Consent Form- ECOG performance status (PS) 0-1- Life expectancy $>$ 3 months- HER2/neu negative patients and patients with HER2/neu positive status but not eligible to trastuzumab therapy in discretion of the investigator- Adequate cardiac, hepatic, renal, hematologic function
Ausschlusskriterien	<ul style="list-style-type: none">- Prior severe allergic reaction or intolerance to a monoclonal antibody, to the chemotherapeutics used in this study or any excipient in the respective formulations- Previous chemotherapy for advanced disease- Previous perioperative chemotherapy with curative intention within 6 months of start of study treatment. If interval is longer than 6 months, patients are allowed- Known HIV infection or known symptomatic hepatitis (A, B, C).- Symptomatic cerebral metastases- Pregnancy or breastfeeding- Previous treatments with maximum cumulative doses of epirubicin $>$ 500 mg/m² and/or other anthracyclines and anthracenediones- Known dihydropyrimidine dehydrogenase (DPD) deficiency
Alter	18 Jahre und älter
Molekularer Marker	CLDN18.2

KURZPROTOKOLL
GM-IMAB-001-03

Fallzahl	140
Prüfzentren	Krankenhaus Nordwest GmbH (Rekrutierung beendet) Institut für klinisch-onkologische Forschung Steinbacher Hohl 2-26 60488 Frankfurt am Main Sandra Janowski Tel: 069 7601-4168 janowski.sandra@khnw.de
Sponsor	Ganymed Pharmaceuticals AG (Hauptsponsor)
Förderer	Ganymed Pharmaceuticals AG
Registrierung in anderen Studienregistern	ClinicalTrials.gov NCT01630083 EudraCT 2011-005285-38